Conquering Diseases

Study Of An Investigational Drug Combination For Untreated Acute Myeloid Leukemia (Aml)


Seeking men and women newly diagnosed with untreated acute myeloid leukemia (AML) who are unable to have chemotherapy for a study of an investigational drug in combination with the standard treatment.


Participants in this study will either get the standard treatment with venetoclax and azacitidine or the standard treatment in combination with the investigational drug. Neither the participant nor their doctor will know who is getting the investigational drug. After 1-2 screening visits the study treatment will be given in 28-day cycles. During each of the three cycles there will be between at least 9-12 study visits.

What we're hoping for

We are studying whether adding an investigational drug to the standard treatment for people newly diagnosed with untreated acute myeloid leukemia (AML) who are not eligible to receive chemotherapy is better than the standard treatment alone.

Additional Information Identifier: NCT05079230

 Principal Investigator

Jan  Cerny, MD, PhD

UMass Chan Medical School

 Study Contact

The Cancer  Research Office



UMass Chan University Campus

55 Lake Ave North 

Worcester,MA 01655